NEW YORK, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ --
American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company"
or "AOBO"), a pharmaceutical company dedicated to improving
healthcare through the development, manufacture and
commercialization of a broad range of prescription and
over-the-counter ("OTC") products, today announced the commercial
launch of AOBO Wujia Rongxue Oral Liquid, ("AWRO Liquid"), an OTC
herbal supplement aimed at boosting energy and health, especially
for middle aged and elderly individuals, by strengthening their
kidney function, which is believed to play a critical role in
health according to the doctrines of traditional Chinese medicine.
Mr. Tony Liu, Chairman and CEO of
AOBO, commented, "As the disposable income increases in
China, the demand for health
supplements has also risen rapidly. In China, individuals not
only purchase these supplements for themselves but also as gifts
for others. In fact, gift purchases contribute significantly
to the strong performance of the health supplements market.
Although not so popular in the USA, this gift purchase behavior pattern in
the health supplement market is common place in China. We believe the addition of AWRO Liquid
will complement our existing product offerings as well as
contribute to the growth momentum of our future OTC product
sales."
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over-the-counter products.
Forward-Looking Statements
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-K for the year ended
December 31, 2009, may cause actual
results or events to differ materially from those described in the
forward looking statements in this press release. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether because of new information,
future events, or otherwise.
Contact:
|
|
|
|
ICR, LLC
|
|
Christine Duan or Ashley
Ammon
|
|
646-277-1200
|
|
|
SOURCE American Oriental Bioengineering, Inc.